ACTA NEUROPHARMACOLOGICA ›› 2020, Vol. 10 ›› Issue (3): 47-53.DOI: 10.3969/j.issn.2095-1396.2020.03.009

Previous Articles     Next Articles

Research Progress in Drug Treatment of Alzheimer’s Disease

YANG Xu-hua,DU Shuang,SHEN Li-xia,HAO Jun-rong   

  1. Department of Pharmacy,Hebei North University,Hebei Key Laboratory of Neuropharmacology,Zhangjiakou,075000,China
  • Online:2020-06-26 Published:2021-05-14
  • Contact: 郝军荣,讲师;研究方向:神经药理学及相关药物;Tel:+86-0313-4029306,E-mail:haojunrong3@163.com
  • About author:杨旭华,2016 级本科生;研究方向:神经药理学;E-mail:706674404@qq.com
  • Supported by:
    河北省自然基金项目( No. H2019405057);河北省高等学校科学技术研究项目(No. ZD2020136)

Abstract:

Alzheimer’s disease has caused a serious of public health problem,there are only two classes of drugs have been approved by FDA to treat the AD presently,but these medicines can only control the symptoms of AD,they can’t delay or block the progress of the disease process. This article first summarized the pathogenesis of AD,and then introduced two types of drugs used to treat AD which is approved by the FDA currently:cholinesterase inhibitors and NMDA receptor blockers. Finally,based on the possible mechanism of neural degenerative diseases we discussed the potential drugs for the treatment of AD,so as to provide evidences for the development of new AD drugs in the future.

Key words: Alzheimer’s disease, drug therapy, dathogenesis

CLC Number: